The Seasonal Influenza Vaccines Therapeutics Market is estimated to be valued at USD 10.2 billion in 2025 and is projected to reach USD 24.1 billion by 2035, registering a compound annual growth rate (CAGR) of 9.0% over the forecast period.
| Metric | Value |
|---|---|
| Seasonal Influenza Vaccines Therapeutics Market Estimated Value in (2025 E) | USD 10.2 billion |
| Seasonal Influenza Vaccines Therapeutics Market Forecast Value in (2035 F) | USD 24.1 billion |
| Forecast CAGR (2025 to 2035) | 9.0% |
The seasonal influenza vaccines therapeutics market is witnessing sustained growth as public health priorities, vaccination awareness, and technological innovations in vaccine production converge to drive demand. The increasing burden of seasonal flu outbreaks coupled with evolving viral strains has underscored the critical role of effective vaccination strategies.
Regulatory emphasis on immunization programs and the introduction of advanced manufacturing techniques have improved both accessibility and efficacy of vaccines. Future expansion is expected to be supported by rising vaccination coverage in developing regions, heightened preparedness initiatives, and continued investments in research for broader-spectrum and longer-lasting immunizations.
Greater focus on protecting vulnerable populations, coupled with collaborations between governments and pharmaceutical companies, is paving the way for a more resilient and responsive market environment.
The market is segmented by Vaccine Type, Age Group, Route Of Administration, and Distribution Channel and region. By Vaccine Type, the market is divided into Quadrivalent and Trivalent. In terms of Age Group, the market is classified into Adult and Paediatric. Based on Route Of Administration, the market is segmented into Injections and Nasal Spray. By Distribution Channel, the market is divided into Hospital Pharmacies, Retail Pharmacies, and Others. Regionally, the market is classified into North America, Latin America, Western Europe, Eastern Europe, Balkan & Baltic Countries, Russia & Belarus, Central Asia, East Asia, South Asia & Pacific, and the Middle East & Africa.
When segmented by vaccine type, the quadrivalent segment is expected to hold 64.5% of the total market revenue in 2025, establishing itself as the leading segment. This dominance is attributed to the enhanced protection offered by quadrivalent vaccines, which target four influenza virus strains instead of three, improving coverage and reducing mismatch risk.
The broader spectrum has been favored by healthcare providers and policymakers as it aligns with evolving epidemiological patterns of influenza viruses. Advances in manufacturing processes have facilitated scalable production of quadrivalent formulations without significantly increasing costs, further supporting their widespread adoption.
The perceived improvement in efficacy and reduced public health burden associated with their use have reinforced their leadership in the market.
Segmented by age group, the adult segment is projected to account for 71.0% of the seasonal influenza vaccines therapeutics market revenue in 2025, maintaining its leading position. This prominence has been driven by the higher susceptibility of adults to flu-related complications, particularly among the elderly and those with chronic conditions.
Public health campaigns have focused intensively on adult vaccination due to their role in workforce productivity and caregiving responsibilities. The convenience of workplace and pharmacy-based vaccination programs has improved access and uptake among this group.
Furthermore, increased awareness of the benefits of vaccination in preventing severe outcomes and minimizing healthcare costs has reinforced the prioritization of adult immunization efforts, sustaining this segment’s leadership.
When segmented by route of administration, injections are expected to capture 88.0% of the market revenue in 2025, solidifying their position as the dominant segment. This leadership is supported by the long-standing acceptance of injectable vaccines as the standard delivery method, offering proven efficacy and predictable immune response.
The infrastructure and expertise to administer injections are well-established across healthcare systems, contributing to their continued preference. Additionally, innovations in needle technology and formulation stability have minimized discomfort and improved patient compliance.
While alternative routes have emerged, injections have maintained their advantage due to reliability, cost-effectiveness, and integration into existing immunization programs, ensuring their continued dominance in the market.
Governments from all across the world are taking steps to encourage the use of the influenza vaccine. They are also researching the adverse reactions to the particular vaccine. Additionally, it is predicted that these elements will drive sales of influenza vaccines. Additionally, the incorporation of the influenza vaccine and growing routine immunization programs in both developed and developing countries are projected to expand sales opportunities in the seasonal influenza vaccine therapeutics market.
Major healthcare organizations are devoting a significant amount of resources and time to the creation of vaccinations as forms of advanced therapy. For instance, Seqirus invested in self-amplifying mRNA's upcoming influenza vaccine technology in August 2024.
In a report released in September 2024 by the CDC, it was said that because seasonal influenza viruses are continually evolving, vaccinations must likewise change to keep up. The market for therapeutic seasonal influenza vaccine therapeutics is expanding as a result of this aspect.
The market for influenza vaccines in North America currently accounts for the largest share, and it is anticipated that this market will grow even more throughout the projected period. This is a result of increased public awareness of viral infections and treatment options, government funding for education campaigns, and scientific developments in the creation of new vaccinations.
Apart from North America, the European market is the second market leader due to a variety of factors including an aging population, an increase in the occurrence of the flu and other related illnesses, and a high need for new vaccine development in the area.
The Asia Pacific region is also expected to uplift the revenue of the seasonal influenza vaccine therapeutics market. Due to the rising prevalence and incidence of influenza in this region, increased government support and surveillance about the influenza vaccine, and increased investment in the region by top global market participants.
CSL Seqirus, Merck, GlaxoSmithKline, Pfizer, Novartis, Sanofi, AstraZeneca, Abbott, SINOVAC, and F. Hoffman-La Roche Ltd. are the major players in the market.
| Report Attributes | Details |
|---|---|
| Growth Rate | CAGR of 9.0% from 2025 to 2035 |
| Base Year for Estimation | 2024 |
| Historical Data | 2012 to 2024 |
| Forecast Period | 2025 to 2035 |
| Qualitative Units | Revenue in USD Billion, and CAGR from 2025 to 2035 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segment Covered | Vaccine Type, Age Group, Route of Administration, Distribution Channel, Region |
| Region Covered | North America; Latin America; Europe; East Asia; South Asia; Oceania; Middle East & Africa |
| Key Countries Profiled | USA, Canada, Brazil, Mexico, Germany, UK, France, Spain, Italy, China, Japan, South Korea, Malaysia, Singapore, Australia, New Zealand, GCC Countries, South Africa, Israel |
| Key Players | CSL Seqirus; Merck; GlaxoSmithKline; Pfizer; Novartis; Sanofi; AstraZeneca; Abbott; SINOVAC; F. Hoffman-La Roche Ltd. |
| Customization | Available Upon Request |
The global seasonal influenza vaccines therapeutics market is estimated to be valued at USD 10.2 billion in 2025.
The market size for the seasonal influenza vaccines therapeutics market is projected to reach USD 24.1 billion by 2035.
The seasonal influenza vaccines therapeutics market is expected to grow at a 9.0% CAGR between 2025 and 2035.
The key product types in seasonal influenza vaccines therapeutics market are quadrivalent and trivalent.
In terms of age group, adult segment to command 71.0% share in the seasonal influenza vaccines therapeutics market in 2025.
Explore Similar Insights
Seasonal Influenza Vaccines Therapeutics Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
Chat With
MaRIA
Get Free Customization